DGAP-News: Invitation to MorphoSys First Quarter Results Conference Call on May 6, 2021 phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Cancer Patients in Asheville Benefit from Major Boost to GenesisCare Surgical Oncology Program
Five highly regarded surgical Oncologists join Comprehensive Cancer Treatment Center Utilizing Artificial Intelligence and Robotics
News provided by
Share this article
ASHEVILLE, N.C., April 29, 2021 /PRNewswire/
GenesisCare one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom today announced the addition of five well-respected surgeons to the Asheville team of GenesisCare USA of North Carolina, PA. GenesisCare Surgical Specialists will be working to put into practice more than 20 life-saving surgical procedures providing comprehensive cancer care across medical and radiation oncology. The collection of comprehensive procedures and surgeons allows the facility to offer treatments for breast, colon, pancreatic, thyroid, skin, and other metastatic cancers.
DGAP-News: Invitation to MorphoSys First Quarter Results Conference Call on May 6, 2021
ACCESSWIRE
Conference Call Alert
Invitation to MorphoSys First Quarter Results Conference Call on May 6, 2021
MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, will publish its results for the first quarter of 2021 on May 5, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys Management Board will host a conference call and webcast on May 6, 2021 at 2:00pm CEST (8:00am EDT) to present the first quarter and first 3-month financial results 2021 and provide an outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
MorphoSys AG: Invitation to MorphoSys First Quarter Results Conference Call on May 6, 2021
Invitation to MorphoSys First Quarter Results Conference Call on May 6, 2021
MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, will publish its results for the first quarter of 2021 on May 5, 2021 at 10:00pm CEST (4:00pm EDT).
MorphoSys Management Board will host a conference call and webcast on May 6, 2021 at 2:00pm CEST (8:00am EDT) to present the first quarter and first 3-month financial results 2021 and provide an outlook for 2021.
The conference call will start with a presentation by the Management Board followed by a Q&A session. Following Board Members will be on the call:
Share this article
Share this article
LONDON, April 28, 2021 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has signed an exclusive license and distribution agreement with AFT Pharmaceuticals (AFT) for the commercialisation of Combogesic
® IV, the US trade name of Maxigesic IV, an intravenous, opioid free post-operative pain relief medicine.
The licensing agreement provides Hikma with exclusive rights for the sales, marketing and distribution of Combogesic
® IV in the US. Combogesic
® IV (paracetamol 1000mg + ibuprofen 300mg solution for infusion) is a patented intravenous formulation developed as a line extension to Maxigesic tablets, for use post-operatively in hospitals when patients cannot take a medicine orally. AFT expects to file Combogesic